BioType

Executive Summary

BioType is a German molecular diagnostics company that has been operational since 2000, headquartered in Dresden. The company specializes in precision medicine for oncology, offering a suite of diagnostic kits, a proprietary testing platform, and contract development and manufacturing services. By focusing on robust analysis and interpretation of clinical biomarkers, BioType enables clinicians to make more informed treatment decisions, which is increasingly critical as the demand for personalized cancer therapies grows. The contract manufacturing arm provides a recurring revenue stream and partnerships with pharmaceutical and biotech firms, reducing dependence on direct product sales. Despite a long history, BioType remains privately held with no disclosed funding or valuation, suggesting it may be self-sustaining or seeking strategic investment. With the molecular diagnostics market expanding at a double-digit CAGR, BioType is well-positioned to capture a share through its established technology and customer relationships.

Upcoming Catalysts (preview)

• Q4 2026CE-IVDR certification of a next-generation oncology biomarker test70% success
• Q2 2027Strategic partnership with a major pharmaceutical company for companion diagnostic development50% success
• H1 2027Series A or growth equity funding round to scale commercial operations40% success